Access Statistics for Mary K. Olson

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Pharmaceutical Expenditure and Regulatory Policy in the NHS 0 0 0 0 0 0 0 329
Total Working Papers 0 0 0 0 0 0 0 329


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Agency Rulemaking, Political Influences, Regulation, and Industry Compliance 0 0 0 0 1 1 2 355
Are novel drugs more risky for patients than less novel drugs? 0 0 1 27 0 0 5 102
Eliminating the U.S. drug lag: Implications for drug safety 0 0 0 10 1 3 7 95
Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity 0 0 0 0 0 3 5 6
Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity 0 1 1 3 0 2 10 37
Firm Characteristics and the Speed of FDA Approval 0 1 2 41 0 2 8 136
New clinical information and physician prescribing: How do pediatric labeling changes affect prescribing to children? 0 1 1 1 0 11 11 11
Pharmaceutical Policy Change and the Safety of New Drugs 0 0 0 3 0 1 10 57
Political Influence and Regulatory Policy: The 1984 Drug Legislation 0 0 0 0 0 1 1 174
Regulatory Agency Discretion among Competing Industries: Inside the FDA 0 0 0 0 0 1 2 175
Regulatory Reform and Bureaucratic Responsiveness to Firms: the Impact of User Fees in the FDA 0 0 0 24 0 0 0 114
Substitution in Regulatory Agencies: FDA Enforcement Alternatives 0 0 0 0 0 0 0 190
The Effects of UK Pharmaceutical Policy on Government Drug Expenditure: Cost Control and Incentives for R&D 0 0 0 12 0 1 1 63
The risk we bear: The effects of review speed and industry user fees on new drug safety 0 0 2 24 0 1 3 117
Total Journal Articles 0 3 7 145 2 27 65 1,632


Statistics updated 2021-04-06